|
Dec 12
|
CEL-SCI Highlights Biological Rationale for the Use of Multikine in the Confirmatory Registration Head and Neck Cancer Study
|
|
Oct 1
|
CEL-SCI Selects Ergomed as CRO as it Gears Up for Confirmatory FDA Registration Study of Multikine® in Head and Neck Cancer
|
|
Sep 4
|
The UK’s Medicines & Healthcare Products Regulatory Agency Grants CEL-SCI a Pediatric Waiver, Bringing Multikine® One Step Closer to Future Marketing Clearance
|
|
Aug 15
|
CEL-SCI Corporation Reports Third Quarter Fiscal 2024 Financial Results
|
|
Aug 15
|
Cel-Sci: Fiscal Q3 Earnings Snapshot
|
|
Jul 29
|
CEL-SCI Announces Closing of $10.8 Million Offering
|
|
Jul 26
|
CEL-SCI Announces Pricing of $10.8 Million Offering
|
|
Jul 26
|
CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results
|
|
Jun 18
|
CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population
|
|
May 8
|
CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer
|
|
Apr 23
|
CEL-SCI Appoints Mario Gobbo to Its Board of Directors
|
|
Apr 15
|
CVM: Parallel Engagement on Four Fronts
|
|
Mar 19
|
CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology
|
|
Mar 6
|
CEL-SCI Corporation Issues Letter to Shareholders
|
|
Dec 22
|
CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments
|
|
Dec 8
|
CVM: NICE To Have Your Support
|
|
Dec 4
|
UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer
|
|
Nov 20
|
CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
|
|
Nov 16
|
CEL-SCI Announces Pricing of $5 Million Offering of Common Stock
|
|
Aug 11
|
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
|